Metabolism of Bradykinin by Peptidases in Health and Disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Publisher Summary This chapter provides an overview of the metabolism of bradykinin (BK) by peptidases in health and disease. The enzymatic breakdown of kinins affects the duration of their biological actions as the plasma half-life of intravenously injected BK is in the range of seconds. Kinins are cleaved in vitro and in vivo by enzymes that belong to families, such as zinc-metallopeptidases, astacin-like metallopeptidases, and catheptic enzymes. Vane noted the importance of the pulmonary circulation in the metabolism of vasoactive substances, such as BK as well as angiotensin 1 and 5- hydroxytryptamine. It is clear after decades of research that angiotensin 1-converting enzyme (ACE) on the vascular endothelial cell surface is the most important inactivator of blood-borne BK. BK may act primarily in an autocrine and paracrine fashion, establishing the importance of local regulation of its activity by enzymes on cell surfaces. Thus, the assortment of other enzymes that can inactivate BK is important in a variety of physiological and pathological situations. Most physiological systems have redundant pathways of metabolism so that the abolishment of one pathway is compensated for by the presence of others. This is demonstrated by the pharmacological inhibition of ACE in hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioregulation of kinins: kallikreins, kininogens, and kininases.
Bhoola, K. D., Figueroa, C. D., & Worthy, K. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00058-4 · Cited by 1,744
Angiotensin-Converting Enzyme Inhibitors
Brown, N. J., & Vaughan, D. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1411 · Cited by 958
Israili, Z. H., & Hall, W. D. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-3-234 · Cited by 910 · cited 2×
“Whether or not coughing, a prominent side effect of ACE inhibitors (Israili and Hall, 1992; Semple, 1995) is caused by prolongation of the haft-life of B K or by potentiation of BK's effects is unclear.”
BackgroundMolecular defect in combined beta-galactosidase and neuraminidase deficiency in man.
D'Azzo, A., Hoogeveen, A., Reuser, A. J., Robinson, D., & Galjaard, H. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.15.4535 · Cited by 365
Galjart, N. J., Gillemans, N., Harris, A., van der Horst, G. T. J., Verheijen, F. W., Galjaard, H., & d'Azzo, A. (1988) · Cell · doi:10.1016/s0092-8674(88)90999-3 · Cited by 220
Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung.
Prechel, M. M., Orawski, A. T., Maggiora, L. L., & Simmons, W. H. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12164-2 · Cited by 102
Identification and in Vitro Reconstitution of Lysosomal Neuraminidase from Human Placenta
van der Horst, G. T. J., Galjart, N. J., d'Azzo, A., Galjaard, H., & Verheijen, F. W. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85088-3 · Cited by 97
Hooper, N. M., Hryszko, J., & Turner, A. J. (1990) · Biochemical Journal · doi:10.1042/bj2670509 · Cited by 91 · cited 7×
“Under denaturing conditions in SDS-PAGE, aminopeptidase P runs as a singlechain protein with an M r = 90,000-95,000, and is a glycoprotein containing about 17-25% carbohydrate by weight (Hooper et al., 1990; Simmons and Orawski, 1992; Orawski and Simmons, 1995) .”
BackgroundInfluentialMouse "protective protein". cDNA cloning, sequence comparison, and expression.
Galjart, N. J., Gillemans, N., Meijer, D., & d'Azzo, A. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39616-4 · Cited by 76 · cited 1×
“Both enzymes are distributed ubiquitously and mRNA expression is highest in human placenta, lung and liver for prolylcarboxypeptidase (Tan et al., 1993) , and mouse kidney and placenta for deamidase/protective protein (Galjart et al., 1990) .”
Background
Cited by
The Kallikrein-Kinin System: Current and Future Pharmacological Targets
Moreau, M. E., Garbacki, N., Molinaro, G., Brown, N. J., Marceau, F., & Adam, A. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.srj05001x · Cited by 457
Bradykinin and des-Arg9-bradykinin metabolic pathways and kinetics of activation of human plasma
Cyr, M., Lepage, Y., Blais, C., Gervais, N., Cugno, M., Rouleau, J.-L., & Adam, A. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.1.h275 · Cited by 160
“Angiotensin-converting enzyme (ACE) constitutes the main degradation pathway that transforms BK into its final inactive metabolite BK(1–5) (13, 15).”
BackgroundInfluentialMolinaro, G., Cugno, M., Perez, M., Lepage, Y., Gervais, N., Agostoni, A., & Adam, A. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038067 · Cited by 137
The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins
Blais, C., Marceau, F., Rouleau, J.-L., & Adam, A. (2000) · Peptides · doi:10.1016/s0196-9781(00)00348-x · Cited by 135
Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema
Lefebvre, J., Murphey, L. J., Hartert, T. V., Jiao Shan, R., Simmons, W. H., & Brown, N. J. (2002) · Hypertension · doi:10.1161/hy0202.103054 · Cited by 113
Metadata
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolism of Bradykinin by Peptidases in Health and Disease. https://app.cochat.ai/papers/10.1016/b978-012249340-9/50009-7
- The paper
- Erdös, E. G., & Skidgel, R. A. (1997). Metabolism of Bradykinin by Peptidases in Health and Disease. The Kinin System. https://doi.org/10.1016/b978-012249340-9/50009-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.